Cancer Metabolism

Dr. Gautam Sethi is a tenured Associate Professor in the Department of Pharmacology at the Yong Loo Lin School of Medicine, National University of Singapore. His research focuses on elucidating the molecular mechanisms underlying cancer initiation and progression, particularly the activation of oncogenic transcription factors by carcinogens and inflammatory agents, and the identification of novel therapeutic inhibitors. Dr. Sethi has made substantial and direct scholarly contributions to the fields of gut microbiota, cancer pathophysiology, and host–microbiome interactions, with particular emphasis on immunotherapy, tumor microenvironment modulation, metabolic signaling, and therapy response prediction. He has authored numerous peer‑reviewed research and review articles in high‑impact journals, received multiple international awards, and serves on the editorial boards of more than 15 international journals. Arun Kumar Singh is an Assistant Professor in the Department of Pharmacy at University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran , India. He completed his M.Pharm in Pharmaceutics from Galgotias University, Greater Noida. His research interests include nano-formulation, blockchain, IoT, machine learning, artificial intelligence, big data analytics, cancer biology, and neuroscience. He has contributed to academic books and book chapters and has published review articles in the areas of pharmaceutical sciences and healthcare technology. His work focuses on interdisciplinary approaches integrating pharmaceutical research with emerging digital and computational technologies. Dr. Hitesh Chopra, PhD currently at Saveetha School of Engineering is working in primarily area of interest includes nanoformulations, natural polymers, cancer, and wound healing and metabolic disorders. He has authored several papers in high-repute journals with total impact factor more than 1000 Dr Milad Ashrafizadeh is a researcher in Sabanci university, Turkey and obtained his degree in field of Veterinary Medicine in 2020. He is an invited scholar in University of Electronic Science & Technology of China. Currently, Milad is an Editorial Board in journal of nanostructure in chemistry (IF= 6.39) and is a review editor in Frontiers journals. He has published review and research articles in international and famous journals in world. Milad has also 4 book chapters. He has published articles in high quality journals including Nanotoday, Coordination Chemistry Reviews, Advanced Science, Carbohydrate Polymers, Journal of Controlled Release and Advances in Colloid and Interface Science, among others. His interests include nanomedicine, application of nanoparticles for drug and gene delivery, targeted cancer therapy, non-coding RNAs in cancer and development of biosensors. Dr. Amir Reza Aref is a scientist at the Belfer Center of Applied Cancer Science, within the Dana-Farber Cancer Institute at Harvard Medical School. He made the important discovery in that it is possible to culture primary tumors in a novel 3D microfluidic system, by digesting them with collagenase and capturing spheroids that are composed of a mixture of tumor and immune cells. In addition, he has demonstrated the ability to treat these tumor spheroids with small molecule inhibitors and measure cytokine responses by collecting conditioned media from the device. This innovative technology is a major advance upon traditional 2D cell line culture and even organoid systems, which require time to establish and lack the immune microenvironment. Furthermore, it enables tumor cytokine profiling in a way not previously possible. Prior to joining the Belfer, he was an Instructor and a research fellow in the Medical Oncology Division at Harvard Medical School, where he characterized Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit in lung tumorigenesis which was resulted to start a new clinical trial at DFCI under supervision of Dr. David Barbie in 2015. He has also completed his post-doctoral in the Biological Engineering Department at MIT between 2009 and 11.

• 1. An introduction to cancer metabolism2. Cancer development and metabolic disorders: Potential Role of metabolic disorders in cancer progression.3. The New Metabolic Therapy: A Key to a Revolutionary Approach to Cancer Treatment4. The changing molecular nature of autophagy in cancer metabolism5. Autophagy and tumor cell metabolism as potential treatment approaches6. The role of autophagy in the control of cancer and its therapeutic applications at the present time7. Cancer-associated fibroblasts and autophagy: biology and targeting8. Mechanisms of signal transduction in solid tumor metabolic dysregulation9. Cancer medication development based on autophagy and metabolic control10. Involvement of mitophagy in metabolic reprogramming in tumors and cancer stem cells11. Changes in Glycolysis and Lipid Metabolism as Molecular Properties of Cancer Cells12. Cancer metabolism molecules and pathways elucidated and therapeutic implications13. Molecular understanding of cancer metabolism: Metabolic interactions within tumor microenvironments, and therapeutic implications14. Targeting cancer metabolism as a potential therapeutic strategy15. Metabolic Pathways in Cancer: Phenotype, Signalling, and Potential Therapeutic Agents16. Cancer Metabolism: Immune System Regulation and Metabolism Mechanisms in Cancer Development